C
Carol Sawka
Researcher at University of Toronto
Publications - 84
Citations - 7890
Carol Sawka is an academic researcher from University of Toronto. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 36, co-authored 83 publications receiving 7083 citations. Previous affiliations of Carol Sawka include Cancer Care Ontario & Women's College, Kolkata.
Papers
More filters
Journal ArticleDOI
Physicians' Opinions About Decision Aids for Patients Considering Systemic Adjuvant Therapy for Axillary-Node Negative Breast Cancer.
TL;DR: There is considerable consensus regarding the indications for, content and criteria for evaluating decision aids which should be considered when developing aids relevant to the needs of clinicians and patients.
Journal ArticleDOI
Outcomes of surveillance mammography after treatment of primary breast cancer: a population-based case series.
Lawrence Paszat,Rinku Sutradhar,Eva Grunfeld,Corona Gainford,Veronique Benk,Susan J. Bondy,Doug Coyle,Claire M. B. Holloway,Carol Sawka,Carol Sawka,Rene Shumak,Katherine A. Vallis,Carl van Walraven +12 more
TL;DR: The association of exposure to ≥1 episode(s) of SM with the risk of death from breast cancer among the study population, and separately among women experiencing CRICB or CPBC.
Journal ArticleDOI
Quality of hospital discharge and physician data for type of breast cancer surgery.
TL;DR: Overall, definitive surgical procedure in the two administrative databases accurately reflected information recorded in patients' charts.
Journal ArticleDOI
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis
Sara Khor,Jaclyn Beca,Jaclyn Beca,Murray Krahn,David R. W. Hodgson,Linda Lee,Michael Crump,Karen E. Bremner,Jin Luo,Muhammad Mamdani,Muhammad Mamdani,Chaim M. Bell,Chaim M. Bell,Carol Sawka,Scott Gavura,Terrence Sullivan,Terrence Sullivan,Maureen E. Trudeau,Stuart Peacock,Jeffrey S Hoch +19 more
TL;DR: The results showed that the addition of rituximab to standard CHOP chemotherapy was associated with improvement in survival but at a higher cost, and was potentially cost-effective by standard thresholds for patients <60 years old, suggesting that ritUXimab may be not as economically attractive in the very elderly on average.
Journal ArticleDOI
Association between extent of axillary lymph node dissection and patient, tumor, surgeon, and hospital factors in patients with early breast cancer.
TL;DR: Which patient, tumor, surgeon, and hospital characteristics are associated with the number of nodes excised in early breast cancer patients are determined.